BLRX
Price:
$0.6136
Market Cap:
$55.61M
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in...[Read more]
Industry
Biotechnology
IPO Date
2011-07-27
Stock Exchange
NASDAQ
Ticker
BLRX
According to BioLineRx Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is -1.36. This represents a change of 75.76% compared to the average of -0.77 of the last 4 quarters.
The mean historical PE Ratio of BioLineRx Ltd. over the last ten years is -2.84. The current -1.36 PE Ratio has changed 4.69% with respect to the historical average. Over the past ten years (40 quarters), BLRX's PE Ratio was at its highest in in the June 2024 quarter at 23.09. The PE Ratio was at its lowest in in the March 2024 quarter at -22.38.
Average
-2.84
Median
-2.89
Minimum
-5.16
Maximum
-0.82
Discovering the peaks and valleys of BioLineRx Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 133.28%
Maximum Annual PE Ratio = -0.82
Minimum Annual Increase = -68.27%
Minimum Annual PE Ratio = -5.16
Year | PE Ratio | Change |
---|---|---|
2023 | -1.66 | 3.13% |
2022 | -1.61 | -49.65% |
2021 | -3.20 | 133.28% |
2020 | -1.37 | 67.62% |
2019 | -0.82 | -68.27% |
2018 | -2.58 | -36.47% |
2017 | -4.06 | 24.64% |
2016 | -3.26 | -29.74% |
2015 | -4.64 | -10.13% |
2014 | -5.16 | 44.17% |
The current PE Ratio of BioLineRx Ltd. (BLRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.16
5-year avg
-1.73
10-year avg
-2.84
BioLineRx Ltd.’s PE Ratio is greater than Ardelyx, Inc. (-20.16), greater than Lexicon Pharmaceuticals, Inc. (-2.49), less than Seres Therapeutics, Inc. (-0.89), greater than ImmunityBio, Inc. (-3.88), less than X4 Pharmaceuticals, Inc. (7.41), greater than Mereo BioPharma Group plc (-18.18), greater than Inozyme Pharma, Inc. (-3.48), greater than Terns Pharmaceuticals, Inc. (-6.06), greater than Leap Therapeutics, Inc. (-1.83), less than Verrica Pharmaceuticals Inc. (-1.02), greater than Verona Pharma plc (-17.02), less than Galera Therapeutics, Inc. (-0.14), greater than Arcutis Biotherapeutics, Inc. (-6.44), greater than Protalix BioTherapeutics, Inc. (-4.99), less than Cidara Therapeutics, Inc. (-0.46), less than Fortress Biotech, Inc. (-0.71), less than Mustang Bio, Inc. (-0.20), less than Achilles Therapeutics plc (-0.45), less than Aptose Biosciences Inc. (-0.15), less than Fortress Biotech, Inc. (-0.71),
Company | PE Ratio | Market cap |
---|---|---|
-20.16 | $1.32B | |
-2.49 | $582.00M | |
-0.89 | $145.36M | |
-3.88 | $2.35B | |
7.41 | $109.78M | |
-18.18 | $664.26M | |
-3.48 | $312.42M | |
-6.06 | $549.60M | |
-1.83 | $107.52M | |
-1.02 | $81.50M | |
-17.02 | $2.14B | |
-0.14 | $4.08M | |
-6.44 | $1.21B | |
-4.99 | $73.54M | |
-0.46 | $80.52M | |
-0.71 | $40.38M | |
-0.20 | $10.22M | |
-0.45 | $29.58M | |
-0.15 | $6.57M | |
-0.71 | $44.00M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioLineRx Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like BioLineRx Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is BioLineRx Ltd.'s PE Ratio?
How is the PE Ratio calculated for BioLineRx Ltd. (BLRX)?
What is the highest PE Ratio for BioLineRx Ltd. (BLRX)?
What is the 3-year average PE Ratio for BioLineRx Ltd. (BLRX)?
What is the 5-year average PE Ratio for BioLineRx Ltd. (BLRX)?
How does the current PE Ratio for BioLineRx Ltd. (BLRX) compare to its historical average?